ArticlePharmaceutics2022

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells.

Sahar Eljack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.